Valsacombi 160 mg/25 mg filmom obložene tablete
| Name | Valsacombi 160 mg/25 mg filmom obložene tablete |
|---|---|
| Marketing Authorisation Number | HR-H-873121320 |
| Active Substance | valsartan hidroklorotiazid |
| Composition | jedna filmom obložena tableta sadrži 160 mg valsartana i 25 mg hidroklorotiazida |
| Pharmaceutical Form | filmom obložena tableta |
| Manufacturer | Krka d.d. Novo mesto, Novo Mesto, Slovenija Krka - farma d.o.o., Zagreb, Hrvatska |
| Marketing Authorisation Holder | Krka - farma d.o.o., Radnička cesta 48, Zagreb, Hrvatska |
| Marketing Authorisation Date | 09.11.2020 |
| MA Period of Validity | unlimited |
| Classification Number | UP/I-530-09/18-02/246 |
| Registration Number | 381-12-01/154-20-04 |
| Prescription | Medicinal product subject to medical prescription |
| Type of prescription | ponovljivi recept |
| Distribution | Supply through pharmacies (community) |
| Advertising to general public | not allowed |
| ATC Code | C09DA03 |
| Marketing status | stavljeno u promet |
| Shortage status | nema nestašice |
| SmPC | download |
| PL | download |
Packaging
Direct Healthcare Professional Communication
| Name | Date | Download |
|---|---|---|
| Pismo zdravstvenim radnicima o riziku od nemelanomskog raka kože povezanog s primjenom hidroklorotiazida | 17.10.2018 | Alkaloid, Belupo, Berlin-Chemie Menarini, Boehringer Ingelheim International, Farmal, Genericon, Pharma, Jadran Galenski laboratorij, Krka - farma, Merck, Merck Sharp & Dohme, Novartis, PharmaSwiss, Pliva, Sandoz, sanofi-aventis i Stada |
